Clinical trial
Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients…
NCT00408239 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00408239 |
|---|---|
| Title | Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement |
| Official title | Factor Xa Inhibitor YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement: A Randomized, Enoxaparin-controlled, Open Label, Dose-escalation Study |
| Acronym | PEARL-1 |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Thromboembolism |
| Intervention type | Drug |
| Interventions | YM150, enoxaparin |
| Enrollment | 367 |
| Start date | Dec 1, 2006 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Dec 6, 2006 |
| Last update posted | Dec 19, 2011 |
| Countries | Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: